Online citations, reference lists, and bibliographies.
← Back to Search

Triple-negative Invasive Breast Cancer On Dynamic Contrast-enhanced And Diffusion-weighted MR Imaging: Comparison With Other Breast Cancer Subtypes

J. H. Youk, E. J. Son, J. Chung, J. Kim, E. Kim
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
AbstractObjectivesTo determine the MRI features of triple-negative invasive breast cancer (TNBC) on dynamic contrast-enhanced MR imaging (DCE-MRI) and diffusion-weighted MR imaging (DWI) in comparison with ER-positive/HER2-negative (ER+) and HER2-positive cancer (HER2+).MethodsA total of 271 invasive cancers in 269 patients undergoing preoperative MRI and surgery were included. Two radiologists retrospectively assessed morphological and kinetic characteristics on DCE-MRI and tumour detectability on DWI. Apparent diffusion coefficient (ADC) values of lesions were measured. Clinical and MRI features of the three subtypes were compared.ResultsCompared with ER+ (n = 119) and HER2+ (n = 94), larger size, round/oval mass shape, smooth mass margin, and rim enhancement on DCE-MRI were significantly associated with TNBC (n = 58; P < 0.0001). On DWI, mean ADC value (×10−3 mm2/s) of TNBC (1.03) was higher than the mean ADC values for ER+ and HER2+ (0.89 and 0.84; P < 0.0001). There was no difference in tumour detectability (P = 0.099). Tumour size (P = 0.009), mass margin (smooth, P < 0.0001; irregular, P = 0.020), and ADC values (P = 0.002) on DCE-MRI and DWI were independent features of TNBC.ConclusionsIn addition to the morphological features, higher ADC values on DWI were independently associated with TNBC and could be useful in differentiating TNBC from ER+ and HER2+.Key Points• Triple-negative breast cancers (TNBC) lack oestrogen/progesterone receptors and HER2 expression/amplification. • TNBCs are larger, better defined and more necrotic than conventional cancers. • On MRI, necrosis yields high T2-weighted signal intensity and ADCs. • High ADC values can be useful in diagnosing TNBC.
This paper references
10.1002/jmri.10140
Differentiation of clinically benign and malignant breast lesions using diffusion‐weighted imaging
Y. Guo (2002)
10.1053/j.ro.2010.09.004
Triple-negative breast cancer: what the radiologist needs to know.
G. Whitman (2011)
Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
D. Allred (1998)
10.1002/jmri.21884
Diffusion‐weighted imaging of breast cancer: Correlation of the apparent diffusion coefficient value with prognostic factors
S. Kim (2009)
10.2214/AJR.09.2355
Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI.
B. Dogan (2010)
10.1056/NEJMOA021967
A gene-expression signature as a predictor of survival in breast cancer.
M. J. van de Vijver (2002)
10.1200/JCO.2007.11.9610
Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology.
D. Hamstra (2007)
10.1007/S12094-008-0265-Y
Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
A. Sánchez-muñoz (2008)
10.1016/j.breast.2010.12.007
Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour.
V. Lorgis (2011)
cancer for tumour grade , estrogen receptor , progesterone receptors and human epidermal receptor - 2 status between core needle biopsy and surgical excisional primary tumour
K Tamaki (2010)
10.2214/AJR.174.6.1741769
Breast Imaging Reporting and Data System: inter- and intraobserver variability in feature analysis and final assessment.
W. Berg (2000)
10.1593/NEO.81328
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.
A. Padhani (2009)
10.1148/radiol.2542090405
Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings.
R. Woodhams (2010)
10.1148/radiol.2503081054
Triple-negative breast cancer: correlation between MR imaging and pathologic findings.
T. Uematsu (2009)
10.1007/s10549-010-1293-1
Triple negative breast cancer: unmet medical needs
S. Pal (2010)
10.1002/jmri.22400
Correlation of the apparent diffusion coefficient value and dynamic magnetic resonance imaging findings with prognostic factors in invasive ductal carcinoma
S. K. Jeh (2011)
10.1007/s10549-009-0499-6
Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response
J. J. Ronde (2009)
10.1073/pnas.191367098
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T. Sørlie (2001)
10.1016/j.crad.2010.07.008
Diffusion-weighted imaging in breast cancer: relationship between apparent diffusion coefficient and tumour aggressiveness.
M. Costantini (2010)
10.1002/nbm.1503
Invasive ductal carcinoma: correlation of apparent diffusion coefficient value with pathological prognostic factors
A. Razek (2010)
10.1007/s00330-011-2061-2
Vascular characterisation of triple negative breast carcinomas using dynamic MRI
S. Li (2011)
10.1001/JAMA.295.21.2492
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
L. Carey (2006)
10.1038/35021093
Molecular portraits of human breast tumours
C. Perou (2000)
10.2214/AJR.10.5515
Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges.
D. Koh (2011)
10.1016/j.mric.2010.09.001
Diffusion magnetic resonance imaging of the breast.
Fernanda Philadelpho Arantes Pereira (2011)
10.1148/RADIOLOGY.211.1.R99AP38101
Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?
C. Kuhl (1999)
10.1158/1078-0432.CCR-06-3045
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
R. Dent (2007)
10.1136/jcp.54.1.20
Preoperative assessment of prognostic factors in breast cancer
H. Denley (2001)
10.1097/RMR.0000000000000037
Breast Imaging Reporting and Data System Category 3 for Magnetic Resonance Imaging
K. Lee (2014)
10.1159/000331643
Triple-Negative Breast Cancer: Clinical and Histological Correlations
Z. Elsawaf (2011)
10.1007/s10549-007-9810-6
Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women
Wei-Tse Yang (2007)
10.1007/s10549-011-1697-6
Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation
E. Montagna (2011)
10.1007/s10147-010-0106-1
Clinicopathological features and treatment strategy for triple-negative breast cancer
Y. Yamamoto (2010)
10.1148/radiol.10092021
Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer.
S. Park (2010)
10.1016/j.molonc.2010.04.006
Triple‐negative breast cancer: Present challenges and new perspectives
F. Podo (2010)
10.1093/annonc/mdp234
Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).
M. Arnedos (2009)
10.1111/j.1349-7006.2010.01630.x
Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients
K. Tamaki (2010)
10.1158/1078-0432.CCR-07-4756
Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
C. Desmedt (2008)
Understanding and treating triple-negative breast cancer.
C. Anders (2008)
10.1007/s00330-009-1656-3
Triple-negative breast cancer: correlation between imaging and pathological findings
E. Y. Ko (2009)
10.1007/s11604-007-0187-6
Comparison of 3.0-and 1.5-tesla diffusion-weighted imaging in the visibility of breast cancer
Aoi Matsuoka (2007)
10.1093/ANNONC/MDM504
Triple-negative breast cancer: MRI features in 29 patients.
J.-H. Chen (2007)
10.1002/jmri.21854
Magnetic resonance (MR) differential diagnosis of breast tumors using apparent diffusion coefficient (ADC) on 1.5‐T
Y. Tsushima (2009)



This paper is referenced by
10.1016/j.tranon.2017.05.004
Cone-beam Breast Computed Tomography: CT Density Does Not Reflect Proliferation Potential and Receptor Expression of Breast Carcinoma12
S. Wienbeck (2017)
10.17925/EOH.2013.09.1.21
Current Status and New Developments in Breast Cancer Diagnosis and Detection
D. Tzias (2013)
10.5812/iranjradiol.31386
Immunohistochemical Subtypes of Breast Cancer: Correlation with Clinicopathological and Radiological Factors
Yu-Mee Sohn (2016)
10.1007/s00330-018-5804-5
Differentiation of triple-negative breast cancer from other subtypes through whole-tumor histogram analysis on multiparametric MR imaging
T. Xie (2018)
10.1111/tbj.12756
MR Imaging Findings in Molecular Subtypes of Breast Cancer According to BIRADS System
Lidia Navarro Vilar (2017)
10.1148/radiol.2015150425
Fast and Noninvasive Characterization of Suspicious Lesions Detected at Breast Cancer X-Ray Screening: Capability of Diffusion-weighted MR Imaging with MIPs.
S. Bickelhaupt (2016)
10.1097/MD.0000000000004086
Analysis of factors influencing the degree of detectability on diffusion-weighted MRI and diffusion background signals in patients with invasive breast cancer
S. Y. Hahn (2016)
10.1155/2019/9429761
Combining Diagnostic Imaging and Pathology for Improving Diagnosis and Prognosis of Cancer
O. Schillaci (2019)
10.1186/s43055-020-00210-5
Breast cancer imaging features as a predictor of the hormonal receptor status, HER2neu expression and molecular subtype
Maged Abdelfattah Ali Algazzar (2020)
10.3348/kjr.2020.0093
Diffusion-Weighted Magnetic Resonance Imaging of the Breast: Standardization of Image Acquisition and Interpretation
S. H. Lee (2020)
10.5812/IRANJRADIOL.64889
Comparison of Different Dynamic Contrast Enhanced-Magnetic Resonance Imaging Descriptors and Clinical Findings Among Breast Cancer Subtypes Determined Based on Molecular Assessment
S. Doğan (2018)
10.1016/j.mri.2019.10.001
Triple-negative breast cancer: Pretreatment magnetic resonance imaging features and clinicopathological factors associated with recurrence.
Youn Soo Lee (2019)
Colorectal Liver Metastases Show Similar Microvascular Characteristics for Individual Patients.
L. Horsley (2013)
10.1016/j.ejrad.2016.02.006
Multi-parametric MRI in the early prediction of response to neo-adjuvant chemotherapy in breast cancer: Value of non-modelled parameters.
E. O'flynn (2016)
10.28982/josam.512779
Relation of peritumoral, prepectoral and diffuse edema with histopathologic findings of breast cancer in preoperative 3T magnetic resonance imaging
A. Gemici (2019)
10.3389/fonc.2020.00412
Correlation Between Mammographic Radiomics Features and the Level of Tumor-Infiltrating Lymphocytes in Patients With Triple-Negative Breast Cancer
Hong-wei Yu (2020)
Correlation between Diffusion-Weighted Imaging and Apparent Diffusion Coefficient with Breast Cancer Histopathological Grading
MONA E. MAREY (2017)
10.1016/j.mric.2017.12.011
Role of MR Imaging in Neoadjuvant Therapy Monitoring.
H. Le-Petross (2018)
10.1007/s13139-016-0446-5
Potential Clinical Applications of 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Mammography in Breast Cancer
Ihn-ho Cho (2016)
10.1038/s41598-017-14274-3
Computer-aided evaluation of the correlation between MRI morphology and immunohistochemical biomarkers or molecular subtypes in breast cancer
Sen Jiang (2017)
10.3390/diagnostics10121090
Can MRI Biomarkers Predict Triple-Negative Breast Cancer?
Giuliana Moffa (2020)
10.1002/jmri.25119
Breast cancer molecular subtype classifier that incorporates MRI features
E. Sutton (2016)
10.1002/jmri.24385
Dynamic contrast enhanced‐MRI in rectal cancer: Inter‐ and intraobserver reproducibility and the effect of slice selection on pharmacokinetic analysis
Andreas M. Hötker (2014)
10.4174/astr.2017.93.1.18
Associations between gene expression profiles of invasive breast cancer and Breast Imaging Reporting and Data System MRI lexicon
G. R. Kim (2017)
10.1177/0284185114524197
Quantitative MRI morphology of invasive breast cancer: correlation with immunohistochemical biomarkers and subtypes
M. Bae (2015)
10.18383/j.tom.2016.00247
Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL
W. Li (2016)
10.1007/s00330-019-06510-3
Diffusion-weighted imaging of the breast—a consensus and mission statement from the EUSOBI International Breast Diffusion-Weighted Imaging working group
P. Baltzer (2019)
10.3390/cancers12061682
Multiparametric Analysis of Longitudinal Quantitative MRI Data to Identify Distinct Tumor Habitats in Preclinical Models of Breast Cancer
A. Syed (2020)
10.1148/radiol.2016161444
Supplemental Breast MR Imaging Screening of Women with Average Risk of Breast Cancer.
C. Kuhl (2017)
10.1111/TBJ.12756
MR Imaging Findings in Molecular Subtypes of Breast Cancer According to BIRADS System.
Lidia Navarro Vilar (2017)
10.1016/j.mri.2013.12.013
Research and progress in magnetic resonance imaging of triple-negative breast cancer.
Junfeng Li (2014)
10.1148/radiol.13131073
Apparent diffusion coefficient in estrogen receptor-positive invasive ductal breast carcinoma: correlations with tumor-stroma ratio.
E. Y. Ko (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar